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Abstract
The role of fine needle aspiration biopsy (FNAB) in the evaluation of focal liver lesions has evolved.
Guided FNAB is still useful to procure a tissue diagnosis if clinical, biochemical and radiologic
findings are inconclusive. Major diagnostic issues include: (i) Distinction of benign hepatocellular
nodular lesions from reactive hepatocytes, (ii) Distinction of well-differentiated hepatocellular
carcinoma (WD-HCC) from benign hepatocellular nodular lesions, (iii) Distinction of poorly
differentiated HCC from cholangiocarcinoma and metastatic carcinomas, (iv) Determination of
histogenesis of malignant tumor, and (v) Determination of primary site of origin of malignant tumor.
This review gives a general overview of hepatic FNAB; outlines an algorithmic approach to
cytodiagnosis with emphasis on HCC, its variants and their mimics; and addresses current
diagnostic issues. Close radiologic surveillance of high-risk cirrhotic patients has resulted in the
increasing detection of smaller lesions with many subjected to biopsy for tissue characterization.
The need for tissue confirmation in clinically obvious HCC is questioned due to risk of malignant
seeding. When a biopsy is indicated, core needle biopsy is favored over FNAB. The inherent
difficulty of distinguishing small/early HCC from benign hepatocellular nodular lesions has resulted
in indeterminate reports. Changing concepts in the understanding of the biological behavior and
morphologic evolution of HCC and its precursors; and the current lack of agreement on the
morphologic criteria for distinguishing high-grade dysplastic lesions (with small cell change) from
WD-HCC, have profound impact on nomenclature, cytohistologic interpretation and management.
Optimization of hepatic FNAB to enhance the yield and accuracy of diagnoses requires close
clinicopathologic correlation; combined cytohistologic approach; judicious use of ancillary tests;
and skilled healthcare teams.
Review
Until recently, guided fine needle aspiration biopsy
(FNAB) was accepted as a safe procedure to procure tissue
diagnosis in the management of patients with focal liver
lesions. However, the role of FNAB in the evaluation of
such lesions, especially hepatocellular carcinoma (HCC),
and the diagnostic challenges it poses have evolved [1-4].
Much diagnostic information can be gleaned nowadays
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from an ever-expanding array of tumor markers and
sophisticated imaging modalities. This has obviated the
need, in some practices, for tissue confirmation in clini-
cally obvious HCC. Surveillance of high-risk cirrhotic
patients, has contributed to an increasing detection of
focal liver lesions that are <2 cm in diameter [5,6]. Study
of autopsy material and cirrhotic explants, coupled with
immunohistochemical and/other ancillary techniques,
have led to better understanding of the morphologic evo-
lution and biological behavior of certain hepatocellular
nodular lesions [7-10]. This changing concept in the evo-
lution of HCC and its precursor lesions has great impact
on nomenclature [11], cytohistologic interpretation,
management strategies and treatment outcomes [5,12].
Critical refinement of current histopathologic criteria for
the diagnosis of small ("early") HCC is necessary with
increasing demands for tissue characterization of small
"suspicious" nodules [13-17]. The window of opportunity
in the treatment of HCC is limited as patients tend to
present with advanced cancers.
The review gives an algorithmic approach to the FNAB
diagnosis of focal liver lesions; an overview of current
diagnostic issues concerning hepatic FNAB; problems and
pitfalls in the cytodiagnosis of well-differentiated hepato-
cellular nodular lesions; and diagnostic utility of
immunohistochemistry.
General approach to focal liver lesions
Focal lesions in the liver range from cysts and inflamma-
tory processes to neoplasms, be they benign or malignant,
primary or metastatic [11,18]. This realm of pathology
comes with its share of diagnostic challenges and pitfalls.
Although imaging and tumor markers can provide a diag-
nosis in many instances, tissue confirmation may be war-
ranted under circumstances where the clinical,
biochemical and imaging profiles are not conclusive [19].
A combined smearing and microhistology approach is
strongly recommended [20-24]. Smears are air-dried and
stained with Diff-Quik/May-Grunwald-Giemsa as well as
fixed in 95% alcohol and stained by the Papanicolaou
method. Particulate material is formalin-fixed for prepara-
tion of cell blocks for histologic study and for special and
immunostains. Use of FNAB needles (21 gauge) with cut-
ting mechanism may provide microbiopsy tissue cores.
Apart from cystic/inflammatory conditions, the major
diagnostic issues are: (i) Distinction of benign hepatocel-
lular nodular lesions, namely, macroregenerative nodule
(MRN), dysplastic nodule (DN), focal nodular hyperpla-
sia (FNH) and liver cell adenoma (LCA), from reactive
hepatocytes; (ii) Distinction of well-differentiated HCC
(WD-HCC) from benign hepatocellular nodular lesions;
(iii) Distinction of poorly differentiated HCC (PD-HCC)
from cholangiocarcinoma (CC) and metastatic carcino-
mas; (iv) Determination of histogenesis of malignant
tumor; and (v) Determination of primary site of origin of
malignant tumor.
Algorithmic approach
A diagnostic algorithm for FNAB diagnosis of focal liver
lesions is given in Table 1. The emphasis is on HCC, its
variants, and their differentiation from benign and
malignant mimics [20].
Step 1: Establish category of clinical presentation
A patient may present with a liver mass/es under the fol-
lowing clinical scenarios: (i) Routine medical check-up,
(ii) Chronic liver disease due to, for example, hepatitis B
or C virus infection, and alcoholism, (iii) Known cancer
cases, (iv) Symptomatic patients, and (v) In childhood.
Important relevant data include serum alpha-fetoprotein
(AFP) and carcinoembryonic antigen (CEA) levels,
hepatitis virus markers, results of liver function tests, pres-
ence of cirrhosis, biliary tract disease, calculi, liver fluke
infestation, and history of hormone usage. Radiologic cor-
relation is mandatory.
Step 2: Establish category of radiologic findings
In many instances, a preoperative diagnosis can be
achieved with a high degree of accuracy based on non-
invasive imaging techniques and close clinical correlation.
FNAB is useful in defining those lesions without charac-
teristic imaging appearance. The solid or cystic nature of
the lesion; number, size and location of the lesion/s;
absence or presence of hepatomegaly, cirrhosis, steatosis,
regional lymphadenopathy and calculi; and status of the
biliary tract are important clues to the final diagnosis.
Imaging of liver masses can be divided into two catego-
ries, namely, cystic and solid lesions. The focus is on a
Table 1: Diagnostic algorithm for fine needle aspiration cytology 
of the liver
Patient with liver mass/es
STEP 1: Establish category of clinical presentation
Imaging
STEP 2: Establish category of radiologic findings
Fine needle aspiration biopsy
STEP 3: Establish nature of cytohistologic findings
Ancillary techniques
(special stains, immunohistochemistry)
STEP 4: Further confirm nature of cytohistologic findings
Clinicopathologic correlation
STEP 5: Establish final diagnosis based on multidisciplinary approachCytoJournal 2005, 2:7 http://www.cytojournal.com/content/2/1/7
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rational and pragmatic approach to hepatic FNAB. A list of
entities is given in Table 2 as a working guide.
Step 3: Establish nature of cytohistologic findings
FNAB of normal/reactive liver
The liver parenchyma comprises a heterogeneous popula-
tion of hepatobiliary and related cells, namely, hepato-
cytes, bile duct and ductular epithelia (Figure 1); and
Kupffer, endothelial, mesothelial and inflammatory cells.
Hepatocytes often contain intracytoplasmic inclusions,
such as, fat vacuoles, Mallory bodies and to a lesser extent,
hyaline bodies; as well as intranuclear cytoplasmic inclu-
sions. Pigments, such as lipofuscin (Figure 2), bile and
iron, may be present.
FNAB of liver with large and small cell change
The terms "large cell change" and "small cell change" have
replaced large and small cell dysplasia [18]. Hepatocytes
with large cell change, considered a low-grade lesion,
exhibit both cell and nuclear enlargement with nuclear
atypia but retaining the normal nuclear-cytoplasmic ratio
(N/C) of ≤  1/3, by eyeballing the diameters of the nucleus
and the cell (Figure 3). On the other hand, in small cell
change, considered a high-grade lesion and putative
precancerous link with HCC, the hepatocytes are small
and monotonous with subtle increase in N/C ratio; they
impart an impression of nuclear crowding. Both types of
changes are common in cirrhosis. The atypical cells can
form dysplastic foci (<1 mm diameter) or nodules (>1
Table 2: Cystic and Solid Lesions of the Liver
CYSTIC LESIONS
BENIGN AND MALIGNANT ENTITIES
Congenital cysts
Parasitic cysts: Hydatid cysts
Abscesses: Pyogenic, amebic and fungal abscesses
Granulomas
Inflammatory pseudotumors (can be solid)
Cystic neoplasms: Biliary cystadenoma/cystadenocarcinoma, 
cholangiocarcinoma associated with cystic liver disease, cystic metastases 
(from ovary, pancreas)
SOLID LESIONS
BENIGN ENTITIES
Benign hepatocellular nodular lesions
Regenerative nodules (cirrhosis, nodular regenerative hyperplasia)
Macroregenerative nodule
Dysplastic nodule
Focal nodular hyperplasia
Liver cell adenoma
Focal fatty change
Benign non-hepatocellular nodular lesions
Bile duct adenoma, hamartoma
Hemangioma
Angiomyolipoma
Extramedullary hematopioesis
MALIGNANT ENTITIES
Classic primary liver cancers
Hepatocellular carcinoma (HCC)
Intrahepatic cholangiocarcinoma
Variants of primary liver cancers
Variants of hepatocellular carcinoma:
HCC with fatty change
HCC, clear cell type
HCC, small cell type
HCC, undifferentiated type
HCC, spindle cell type
HCC, giant cell type
Fibrolamellar HCC
HCC with biliary differentiation
Combined hepatocellular-cholangiocarcinoma
Variants of cholangiocarcinoma:
Biliary papillary neoplasia / Intraductal papillary cholangiocarcinoma
Mucinous intrahepatic cholangiocarcinoma
Mimics of primary liver cancers
Adenocarcinoma
Squamous cell carcinoma
Small round cell malignancy
Clear cell malignancy
Pleomorphic cell malignancy
Spindle cell malignancy
Giant cell malignancy
Hepatoid carcinoma; alpha-fetoprotein-producing carcinoma
Normal and reactive hepatocytes: FNAB Figure 1
Normal and reactive hepatocytes: FNAB. Monolayered 
clusters of loosely-cohesive, well-defined, polygonal cells 
with ample dense, granular cytoplasm, round central nuclei 
and low nuclear-cytoplasmic ratio. Note the double-layered 
row of ductular epithelial cells with scanty cytoplasm (May-
Grunwald-Giemsa).CytoJournal 2005, 2:7 http://www.cytojournal.com/content/2/1/7
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mm diameter) in both cirrhotic and non-cirrhotic livers
[18].
FNAB of a liver mass: Stepwise approach
Liver aspirates can come from malignant or benign condi-
tions of hepatocellular or non-hepatocellular origin [25-
27]. Certain entities can give characteristic gross appear-
ances when smeared [20]. Naked eye inspection coupled
with low power scanning view of the smears is a helpful
adjunctive step to determine: (i) Patterns of spread of
smears, (ii) Malignant or benign cell picture, (iii) Hepato-
cytic nature or otherwise, and (iv) Monotonous hepato-
cytic population or heterogeneous liver parenchymal
components.
Normal and reactive hepatocytes: FNAB Figure 2
Normal and reactive hepatocytes: FNAB. (A) Hepatocytes show dense granular cytoplasm, round central nuclei, well-delin-
eated nuclear membrane, distinct nucleoli, granular chromatin and binucleation. Note polymorphism displayed by nonneoplas-
tic hepatocytes. The cells contain brown granules of lipofuscin pigment in the cytoplasm (Papanicolaou). (B) Lipofuscin appears 
as black granules. The two elongated nuclei are likely to be Kupffer cells (May-Grunwald-Giemsa).
Hepatocytes with large cell change: FNAB Figure 3
Hepatocytes with large cell change: FNAB. There is 
simultaneous nuclear and cell enlargement of the hepato-
cytes, thus maintaining the nuclear-cytoplasmic ratio of 1/3. 
Note mild nuclear atypia (Papanicolaou).
Naked eye inspection of hepatic aspirate Figure 4
Naked eye inspection of hepatic aspirate. Uniformly gran-
ular pattern of spread of classic hepatocellular carcinoma. 
Note the regularly irregular tumor fragments which tend to 
be equidistant (Papanicolaou).CytoJournal 2005, 2:7 http://www.cytojournal.com/content/2/1/7
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Patterns of spread of smears
A. Uniformly granular pattern. Hypercellular. Regularly
irregular tissue fragments; evenly distributed in rows with
tendency to be equidistant. Most likely HCC (Figure 4).
B. Non-uniformly granular pattern. Hypercellular. A
mixed picture of irregular tissue fragments of variable
size/shape; may include uniform granules. Variable cell
picture -malignant to benign lesions of any origin.
C. Scanty pattern. Hypocellular. Streaks or fine clumps of
cells. Variable cell picture -desmoplastic malignancies or
benign conditions, such as cyst contents and
hepatocellular nodular lesions. Pitfalls: Necrotic or cystic
neoplasm; non-lesional sample.
D. Fluid pattern. Amorphous look. Thin fluid or thick pus.
Usually benign and non-hepatocellular, such as abscess or
infected cyst contents. Pitfalls: Dissociated tumor cells,
such as lymphomas.
E. Microbiopsy pattern. Short and narrow, difficult-to-
focus tissue cores, usually composed of nonneoplastic
liver parenchyma with intact architecture. Admixed with
other patterns, if the specimen is representative and
includes lesional tissue. The clue is from the other pat-
terns. Rarely, tumor tissue.
FNAB of hepatocellular carcinoma
HCC can be small/focal, solitary/large, and multifocal/
diffuse; with satellite nodules and large vein involvement.
Classic HCC is usually graded into well, moderately or
poorly differentiated lesions. Histologic patterns com-
prise trabecular-sinusoidal, pseudoacinar and solid types;
combinations are frequent [28]. Close attention should
be paid to architectural details in cell blocks/microbiop-
sies and smears. Accurate distinction from metastases,
especially unresectable lesions, is necessary for
Well-differentiated hepatocellular carcinoma with trabecular and pseudoacinar patterns: FNAB Figure 5
Well-differentiated hepatocellular carcinoma with trabecular and pseudoacinar patterns: FNAB. (A) Thick arborizing 
cords of malignant hepatocytes showing cellular monotony, increased nuclear-cytoplasmic ratio, and impression of nuclear 
crowding. The circular spaces among the cords represent pseudoacini (Papanicolaou). (B) Corresponding histologic section of 
the tumor shows trabecular-sinusoidal arrangement with pseudoacini. Note the uniformity of the tumor cells and cords 2 to 3 
cells thick (H&E).
Moderately differentiated hepatocellular carcinoma: FNAB Figure 6
Moderately differentiated hepatocellular carcinoma: 
FNAB. Thick cords of malignant hepatocytes are wrapped by 
peripheral endothelium. They appear to be floating on trans-
verse section view (Papanicolaou).CytoJournal 2005, 2:7 http://www.cytojournal.com/content/2/1/7
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appropriate therapy. One should be aware that there are
limitations to the cytodiagnosis of HCC [23,29-31].
Smears
• Hypercellular smears with uniformly granular pattern of
spread of the cells.
• Cohesive clusters of malignant hepatocytes with arboriz-
ing, tongue-like projections of broad cords (>2 cells thick)
that may be wrapped by peripheral endothelium (Figures
5, 6).
• Rows of transgressing endothelium in larger aggregates;
basement membrane material ("sinusoidal capillariza-
tion") best seen in Giemsa preparations.
• Cohesion is the rule; however, tendency to dissociation
noted in highly WD-HCC and PD-HCC.
• Pseudoacini containing bile or pale secretions are not
uncommon. The spaces are surrounded by polygonal cells
with central nuclei similar to adjacent cells (Figure 7).
• Hepatocytic characteristics include polygonal cells with
well-defined borders, ample granular cytoplasm, central
round nucleus, well-delineated nuclear membrane, prom-
inent nucleolus and fine, irregularly granular chromatin.
Mitoses increase with nuclear grade. Cytologic features of
malignancy are wanting at the highly WD-HCC end
whereas resemblance to hepatocyes is lacking at the PD-
HCC end.
• Tumor cells may be smaller, larger or of the same size as
normal hepatocytes. WD-HCC cells tend to be
conspicuous by their small size, monotony, subtle
increase in N/C ratio and nuclear crowding. PD-HCC cells
tend to be pleomorphic (Figure 8).
• Atypical naked hepatocytic nuclei may abound (Figure
9).
• Multinucleated tumor giant cells may be of "osteoclas-
tic" or pleomorphic type. The former shows nuclear
features akin to adjacent HCC cells. Tumor giant cells may
be found in all grades of HCC. Their presence does not
necessarily upgrade the tumor.
• Bile may be present within tumor cells or in canaliculi
or pseudoacini.
• Intracytoplasmic fat and glycogen vacuoles are com-
mon. Intracytoplasmic inclusions include hyaline, pale
Moderately differentiated hepatocellular carcinoma with pseudoacinar pattern: FNAB Figure 7
Moderately differentiated hepatocellular carcinoma with pseudoacinar pattern: FNAB. (A) Pseudoacini filled with bile 
which appears as dark brown blobs (Papanicolaou) (B) Bile appears black (May-Grunwald-Giemsa). (C) Corresponding histo-
logic section of the tumor shows cystically dilated canaliculi filled with golden-brown bile and surrounded by polygonal cells 
with central nuclei (H&E).
Poorly differentiated hepatocellular carcinoma: FNAB Figure 8
Poorly differentiated hepatocellular carcinoma: FNAB. 
High-grade tumor shows marked pleomorphism but still 
retaining some hepatocytic characteristics (Papanicolaou).CytoJournal 2005, 2:7 http://www.cytojournal.com/content/2/1/7
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and Mallory bodies. Intranuclear cytoplasmic inclusions
are not specific.
• Bile duct epithelial cells, if present, are few and far apart.
Kupffer cells may be seen.
Cell blocks/microbiopsies
• Microhistology provides additional invaluable architec-
tural details such as trabecular-sinusoidal pattern formed
by broad trabeculae (>2 cells thick); pseudoacini;
unpaired arteries; and deficient/virtually absent reticulin
framework.
FNAB of well-differentiated hepatocellular nodular lesions
The accuracy of cytodiagnosis at this end of the spectrum
is often an issue with indeterminate reports being
rendered [14,32]. The diagnostic dilemmas are: (i) Is the
sample representative? (ii) Are the hepatocytes malignant
(highly WD-HCC) or benign? (iii) If benign, are they neo-
plastic (LCA) or nonneoplastic hepatocytes? (iv) If nonne-
oplastic, are they intralesional (FNH, DN or MRN) or
extralesional hepatocytes (cirrhosis  or  normal liver),
with/without fatty change? Cytologic features predictive
of HCC include increased N/C ratio, cellular monomor-
phism, nuclear crowding, trabeculae >2 cells thick, atypi-
cal naked hepatocytic nuclei and lack of bile duct cells
[23,33]. Cytologic parameters distinguishing highly WD-
HCC from cirrhosis include well-defined cytoplasmic bor-
ders, scant cytoplasm, monotonous cytoplasm, thick cyto-
plasm, eccentric nuclei and increased N/C ratio [34].
FNAB of variants of hepatocellular carcinoma
HCC is well known for its histologic variations and sub-
types. A large tumor can harbor areas that are more easily
recognizable than others. This has significant practical
implications on the number of passes and sampling in
hepatic FNAB.
The variants of HCC include:
• HCC with fatty change: Fatty change can occur in HCC
without associated steatosis. Small (early) lesions are
prone to fatty change due to inadequate vascularization.
WD-HCC cells with cytoplasmic fat vacuoles can be mis-
taken for hepatocytes from fatty liver or focal fatty change
(Figure 10) [35,36]. PD-HCC cells with fat vacuoles may
mimic malignant lipoblasts or signet-ring adenocarci-
noma cells.
• HCC, clear cell type: Clear cell change in hepatocytes is
due to abundant cytoplasmic glycogen or lipid content
[37]. Tumor cells with empty-looking vacuoles after
removal of glycogen during processing may mimic fatty
change. Focal clear cell change is frequent. Diffuse clear
cell change occurs in <10% of cases of HCC [38].
• HCC, small cell type: This type is reminiscent of neu-
roendocrine tumors with tendency to dissociation and
microacinar formation but no obvious trabecular pattern
[39,40]. Scrutiny of the nuclear/chromatin features
should reveal the true histogenesis of the small round
cells.
Poorly differentiated hepatocellular carcinoma: FNAB Figure 9
Poorly differentiated hepatocellular carcinoma: FNAB. 
Atypical naked hepatocytic nuclei exhibit pleomorphism, thin 
nuclear membrane, nuclear contour irregularities, prominent 
nucleoli and multinucleation (Papanicolaou).
Fatty change: FNAB Figure 10
Fatty change: FNAB. Hepatocytes exhibit polymorphism 
and contain cytoplasmic fat vacuoles of varying sizes pushing 
nucleus to one side. Cytologic picture can mimic signet-ring 
cell adenocarcinoma (Papanicolaou).CytoJournal 2005, 2:7 http://www.cytojournal.com/content/2/1/7
Page 8 of 16
(page number not for citation purposes)
• HCC, undifferentiated type: The tumor cells are larger
than the small cell category with no obvious hepatocytic
characteristics.
• HCC, spindle cell type: This is rare and is more likely to
be seen with tumor giant cells as part of a larger tumor
[41].
• HCC, giant cell type: This pure variant is rare.
• Fibrolamellar HCC: This occurs in non-cirrhotic livers
of young patients and has a good prognosis. It comprises
large, discohesive polygonal hepatocytes with abundant
oncocytic cytoplasm and lamellar fibrosis. Pale bodies are
common [42,43].
• HCC with biliary differentiation: Some HCC are posi-
tive for biliary markers (AE1/3, CK19) [44]. The stem cell
theory with bipotential progenitor cells capable of
developing into either hepatocytes or biliary epithelial
cells provides a satisfactory explanation for primary liver
cancers arising from different stages of the cell lineage
[45].
•  Combined hepatocellular-cholangiocarcinoma
(CHCC-CC): This is a rare tumor containing unequivocal
elements of HCC and CC that are intimately admixed
with a transitional component [46,47]. The HCC cells are
expected to be AFP and Hep Par 1-positive and show pol-
yclonal CEA (pCEA) canalicular staining. The CC cells are
AE1/3-positive and show brush border/diffuse cytoplas-
mic pCEA reactivity. The intermediate cells exhibit hybrid
features with equivocal immunoprofiles.
FNAB of cholangiocarcinoma and its variants
Intrahepatic CC are rare and usually occur in non-cir-
rhotic livers in close proximity with sizeable bile ducts.
Predisposing diseases include clonorchiasis, opisthorchia-
sis, hepatolithiasis and primary sclerosing cholangitis. CC
are usually well to moderately differentiated adenocarci-
nomas with variable degree of desmoplasia. They can be
categorized into papillary and/or tubular adenocarcino-
mas. Mucin production is minimal. A squamous
component may be present. Adjacent biliary epithelial
changes include carcinoma-in-situ and biliary ductular
proliferation. There are three cytologic smear patterns,
namely (i) Scanty cell smear pattern, (ii) Adenocarcinoma
with proliferating ductular clusters, and (iii) Adenocarci-
noma without prominent ductular clusters [20].
The variants of CC include:
• Biliary papillary neoplasia / intraductal papillary CC
[48]
• Mucinous intrahepatic CC [20]
FNAB of non-hepatocellular carcinoma malignancies
That the liver is a common target for metastases makes the
separation between primary and secondary malignancies
all the more difficult, especially when the particular histo-
logic subtype can arise in the liver as well. Categorizing
them based on cytologic patterns is a good start.
• Adenocarcinoma: Most are metastases from stomach,
colorectum, pancreas, breast and lungs. Colorectal
metastases have much tumor diathesis. Signet-ring cell
adenocarcinomas are likely to be gastric in origin. Pancre-
aticobiliary tract adenocarcinomas can have squamous
components. For any adenocarcinoma in hepatic aspi-
rates, CC, HCC with pseudoacini and CHCC-CC have to
be considered.
• Squamous cell carcinoma: Most are metastatic or arise
in the pancreaticobiliary tract. Large, spindly, "tadpole-
shaped" or bizarre cells with dense cytoplasm, keratiniza-
tion and much necrosis may be seen. Adenosquamous
variants are not uncommon.
•  Small/intermediate round cell malignancy: This
includes neuroendocrine tumors (NET), small cell
undifferentiated carcinomas (SCUC), undifferentiated
nasopharnygeal carcinomas and lymphomas [40,49].
Other possibilities include melanoma, Merkel cell tumor,
metastatic adenocarcinomas from prostate, stomach and
breast (lobular carcinoma), CC, certain sarcomas and
HCC, small cell type. Most NET are from the gastrointes-
tinal tract (GIT), pancreaticobiliary tract or lung; primary
hepatic NET is unusual [50].SCUC usually originates in
the lung. Hepatic metastases from nasopharnygeal carci-
nomas tend to be markedly necrotic mimicking abscesses
radiologically. Lymphoma seldom presents as a primary
neoplasm although hepatic involvement is common in
advanced disease [51]. It has been reported in hepatitis B
virus infection, systemic lupus erythematosus, primary
biliary cirrhosis and acquired immunodeficiency
syndrome. A high index of suspicion is necessary. It can be
mistaken for poorly differentiated carcinoma or HCC.
Inflammatory processes, such as inflammatory pseudotu-
mors [52-54], and sinusoidal hematopoietic cells have
first to be excluded. Nodular extramedullary hematopoie-
sis can rarely mimic metastases.
• Clear cell malignancy: This can also arise in the kidney,
adrenal and ovary [55]. Renal cell carcinoma contains
transgressing endothelium and papillary endothelium in
fibrovascular cores but lacks peripheral endothelium.
Nuclear features also differ. However, renal cell carcinoma
has not been called the great mimic for no good reason.
Metastases can occur years later. Other pitfalls includeCytoJournal 2005, 2:7 http://www.cytojournal.com/content/2/1/7
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hepatocytes with fatty change and metastases from liposa-
rcoma and signet-ring cell adenocarcinoma.
• Pleomorphic cell malignancy: This includes large cell
undifferentiated carcinomas (LCUC), large cell lympho-
mas, germ cell tumors and various sarcomas. LCUC is not
a pure or single entity; tumors may show glandular and
neuroendocrine differentiation. Common sites are lung,
GIT and female genital tract.
•  Spindle cell malignancy: Well-differentiated spindle
cell tumors include leiomyosarcoma (LS), neurogenic
tumors and fibroblastic/stromal tumors, including gas-
trointestinal stromal tumor (GIST) [56]. At the poorly dif-
ferentiated end, LS, malignant fibrous histiocytoma,
undifferentiated sarcoma or even sarcomatoid HCC or CC
with a spindle cell component, have to be considered.
Apart from distinguishing LS  from leiomyoma, other
differential diagnoses include benign reactive processes
[57]. The epithelioid variant of LS occurs primarily in the
GIT. Hepatic metastases can be mistaken for epithelial
tumors, such as, HCC, CC, metastatic carcinoma and
melanoma.  GIST  also has spindle and epithelioid cell
types [58]. Metastatic GIST may pose diagnostic problems
due to their variable morphologic spectrum and cytologic
atypia; c-kit staining is necessary. Hepatic angiosarcoma
associated with Thorotrast and epithelioid hemangioen-
dothelioma are rare. In the young, differential diagnoses
of spindle cell lesions include inflammatory pseudotu-
mor, infantile hemangioendothelioma, mesenchymal
hamartoma and undifferentiated (embryonal) sarcoma.
• Giant cell malignancy: This can be carcinomatous or
sarcomatous. Giant cell carcinomas have been noted in
lung, pancreas, thyroid, kidney and breast. Hepatic metas-
tases have to be distinguished from HCC, giant cell type.
• Hepatoid carcinoma; AFP-producing carcinoma: Pri-
mary hepatic tumors are not the only source of AFP. Nei-
ther is the liver the only site of origin for hepatocytic-
looking carcinomas. Most of them arise in the lung and
GIT. Those with hepatoid features mimic classic HCC in
having a proclivity for vascular permeation and distant
metastases, in this case to the liver. Others produce AFP
but are non-hepatoid; being usually adenocarcinoma,
undifferentiated carcinoma and small or large cell neu-
roendocrine carcinoma [59].
Suffice it to say that when dealing with FNAB of liver
masses, one must be fully aware of any past history of
malignancy or rule out any hitherto undetected cancer.
Some of the limitations in the categorization of tumors
obtained by FNAB can be overcome by immunohisto-
chemistry. The advantages of an exact cytodiagnosis are
obvious – it may save the patient a diagnostic laparotomy,
especially in inoperable cases, and allow for specific
chemotherapy to be instituted without delay. However, at
best, information gleaned from a precise cytodiagnosis
can sometimes only favor a particular primary site.
Step 4: Further confirm nature of cytohistologic findings
The initial cytologic assessment is crucial as it forms the
basis upon which ancillary tests are ordered; the results of
which should be interpreted in the larger context of the
case.
Special stains
• Reticulin
Study of the reticulin framework, stained by Gomori's
method, is important in the analysis of well-differentiated
hepatocellular nodules [60,61]. HCC have deficient or
absent reticulin; the reticulin framework in LCA and FNH
may not be well developed either.
•  Periodic acid-Schiff with and without diastase;
Mucicarmine
This is usually performed to distinguish glycogen from
epithelial mucin. Hepatocytes are loaded with glycogen.
Cells exhibiting glandular (biliary) differentiation may
show intracytoplasmic or intraluminal mucin production.
• Fat
Fat can be demonstrated in nonneoplastic and neoplastic
hepatocytes by staining fresh or formalin-fixed tissue with
Oil Red O. It has no discriminant value in defining the
biological status of hepatocytes but may be of help in
deciphering the contents of cytoplasmic vacuoles of cells
of unrecognizable histogenesis.
• Iron
Iron appears as black cytoplasmic granules in hepatocytes
stained with Giemsa stains and dark brown with
Papanicolaou stains. The pigment can be confirmed with
Perl's prussian blue method. Iron accumulation in hepa-
tocytes favors a benign process. On the other hand, in
populations where hepatic iron accumulation is com-
mon, the absence of iron in hepatocytes should alert one
to the presence of a proliferative process, be it regenerative
or neoplastic.
Immunohistochemistry
A whole battery of antibodies is available for the compar-
ative immunohistochemical study of primary and meta-
static liver tumors. The two major diagnostic issues are (i)
whether the hepatocytes are malignant or benign, and (ii)CytoJournal 2005, 2:7 http://www.cytojournal.com/content/2/1/7
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what the histogenesis of the malignant cells is [See "Diag-
nostic utility of immunohistochemistry"].
Step 5: Establish final diagnosis based on multidisciplinary 
approach
Close clinicopathologic correlation is mandatory for
enhancing the yield of FNAB diagnoses and the reduction
of indeterminate reports.
Current diagnostic issues
Reappraisal of role of hepatic fine needle aspiration 
biopsy
1. It is still to procure a tissue diagnosis as part of the evaluation of 
focal liver lesions but under circumstances where the clinical, 
biochemical and imaging profiles are not conclusive
A benign cytodiagnosis obviates unnecessary surgery. Sur-
gical resection is indicated for any resectable malignant
hepatic mass, be it primary or secondary. In unresectable
malignant lesions, a precise cytohistologic typing is cru-
cial for appropriate alternative therapy. The need for
biopsy diagnosis in HCC is now a hotly debated topic
[2,4,12]. The stand in some practices is that a needle
biopsy may be indicated only if it is not possible to diag-
nose HCC by other means, namely, serum AFP concentra-
tion, spiral computed tomography (CT) and magnetic
resonance imaging (MRI). In advanced HCC, the need for
biopsy may be obviated due to the non-availability of
effective therapy. In early/small HCC, even if a biopsy is
performed, the diagnostic sensitivity of the procedure may
be as low as 60% [3]. If there is a high index of suspicion
for HCC despite negative cytologic sampling, specific
therapy may be instituted.
2. It is a safe and well-tolerated, minimally invasive procedure with 
low risk of complications in suitable candidates and in skilled hands
Needle track seeding by malignant cells is the main reason
often cited by opponents of FNAB of the liver [2,62-64].
There is no reliable data to establish the risk; the figure of
0.006% is regarded as a gross underestimation by many
authors [3,65,66]. Needle biopsies, in general, are usually
not indicated in patients deemed suitable for liver trans-
plantation due to possible seeding [5]. The move to insti-
tute definitive treatment for classic HCC diagnosed solely
on clinical, biochemical and radiologic grounds without
tissue confirmation has crept slowly into some practices.
The risk of false positive diagnosis of HCC with subse-
quent aggressive therapy, such as liver transplantation, by
far outweighs the risk of seeding.
3. It is a technique with high sensitivity and specificity when practised 
in a multidisciplinary setting by skilled operators
Tissue procurement by FNAB under radiologic guidance
and cytologic interpretation of the aspirated material are
both highly operator-dependent. An experienced screener
on-site can give a rapid assessment of adequacy.
4. Surveillance for early HCC in high-risk patients has resulted in the 
detection of "suspicious" nodules in cirrhotic livers that are often <2 
cm in diameter
The usual surveillance tools are serum AFP concentration
and ultrasonography (US). AFP is not a very good screen-
ing test since it has a sensitivity of 39–64%, a specificity of
76–91% and a positive predictive value of between 9–
32% [6,67]. On the other hand, US has, as a screening test
in hepatitis B surface antigen (HBsAg) carriers, a sensitiv-
ity of 71% and specificity of 93%, but its positive predic-
tive value is only 14% [6]. Although a spectrum of
hepatocellular nodular lesions can be encountered, espe-
cially in a background of cirrhosis, studies have revealed
that about half of them are not HCC. Tissue characteriza-
tion is, therefore, mandatory and FNAB may be the sim-
plest and most practical means to reach small, deep-
seated lesions [1].
The European Association for the Study of the Liver (Barce-
lona-2000 EASL Conference) [5]has drawn up guidelines for
the current clinical management of HCC. HCC can be diag-
nosed in a setting of liver cirrhosis if a focal liver lesion is >2
cm in diameter with arterial hypervascularization, and shows
coincident features in at least two imaging techniques (US, spi-
ral CT, MRI and angiography); or characteristic features in one
imaging technique associated with serum AFP level of >400 ng/
ml. It follows then that there is no necessity to obtain cytologic
and/or histologic confirmation for all cases of suspected HCC.
It is recommended that punctures be limited to patients with
nodules <2 cm diameter for the differentiation of HCC from
regenerative nodules. In the future, tumor biopsy may assume a
different role by becoming a useful tool for procuring tissue for
the molecular profiling of the disease. It is important to note
that the above recommendations are not meant for everyone. It
should be carried out in highly selected patients by highly skilled
healthcare teams in specialized tertiary centers.
Fine needle aspiration biopsy versus core needle biopsy
Fine needle aspiration biopsy is useful for (i) cirrhotic
patients with poor liver function with risk of bleeding; (ii)
liver masses with obstructive jaundice and risk of bile
leakage, those near big vessels, or where there is need to
go through bowel; (iii) small (<2 cm diameter), deep-
seated and difficult to approach nodules that require close
patient co-operation during the procedure; (iv) represent-
ative sampling of sizeable lesions by re-direction of the
needle and multiple passes; and (v) on-site rapid assess-
ment of adequacy and rendering of provisional diagnosis,
as well as for appropriate triage of tissue specimens for
ancillary studies (e.g. microbiology, flow cytometry,
genetic testing, molecular diagnostics, cell block prepara-
tion and electron microscopy) [22].
Core needle biopsy (CNB), with the availability of more
material, provides tissue for histologic andCytoJournal 2005, 2:7 http://www.cytojournal.com/content/2/1/7
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immunohistochemical studies, especially in two major
areas of diagnostic difficulties, namely, in the (i) differen-
tiation of WD-HCC from benign hepatocellular nodules;
and (ii) separation of HCC from CC and metastases. A
critical comparative evaluation of the risks of seeding by
CNB and FNAB is needed. For the proponents of CNB, the
view is that a single pass with larger bore needles (<20
gauge) may be preferable to multiple passes by finer
needles needed to obtain sufficient material for cytohisto-
logic examination. The incidence of seeding may increase
as a result of the number of punctures of tumors detected
at an early stage in patients with a longer life expectancy
[66].
Consensus: The diagnostic accuracy in terms of sensitiv-
ity, specificity and positive predictive value of FNAB for
HCC is almost similar to that of CNB. The accuracy rate is
highly operator-dependent and increases with both
techniques combined. The specificity and positive predic-
tive value of FNAB in the diagnosis of malignant hepatic
lesions has been shown to be close to 100% in most stud-
ies [19,22,68,69]. These results are comparable to the
accuracy of CNB. In a comparative study, it was reported
that both procedures, FNAB and CNB, had the same diag-
nostic accuracy of 78% when considered separately and of
88% when considered in combination [21]. The conclu-
sion was that the great advantage of combining the two
techniques was the reduction in false negative results. Per-
forming both procedures at the same sitting may not be
feasible due to medical contraindications and may also
not be acceptable clinical practice. Using larger caliber cut-
ting needle biopsies can be associated with a greater
number of complications [68]. This quagmire can be
overcome by using cutting FNAB needles. At our institu-
tion, the utilization of such (21 gauge) aspiration needles
has provided us with ample material for smear prepara-
tions as well as tissue cores resembling microbiopsies
rather than mere cell blocks [20,34]. Our practice has
been to retrieve sizeable particulate matter from the mate-
rial on the glass slides prior to smearing and fixing them
in formalin for cell block preparation. Many studies have
attested to the improved diagnostic yield and accuracy of
FNAB using the combined cytohistologic approach
[23,70]
FNAB can provide rapid on-site diagnosis when the
smears are stained with Diff-Quik or Ultra-fast Papanico-
laou stain [28]. In the era of rising costs in medical prac-
tice and higher patient/practitioner/institution
expectations of efficiency and faster turn-around time,
FNAB can obviate the need to wait for tissue processing if
accurate cytologic diagnoses can be rendered. Another
cost-saving advantage, especially for less developed coun-
tries, is that smears are cheap, convenient and easy to pre-
pare as long as there is an experienced person to interpret
them.
Considering the overall advantages and cost-analysis,
FNAB can be suggested as the initial method of choice for
evaluation of focal liver lesions in most clinical settings.
The final choice should be decided on the basis of the
working clinical diagnosis and the institutional/personal
experience.
Separation of well-differentiated hepatocellular 
carcinoma from benign hepatocellular nodular lesions
Factors that pose diagnostic problems and pitfalls
1. HCC can be small and focal, solitary and large, multi-
focal, or diffuse and infiltrating; thereby, mimicking small
benign lesions on the one hand and metastases on the
other, especially in imaging studies.
2. Serum AFP, though fairly specific, has poor sensitivity
for the diagnosis of HCC, regardless of tumor size or
degree of differentiation. There is significant elevation in
about 50–60% of HCC [24,33]. Small WD-HCC are usu-
ally not associated with serum AFP elevation. On the
other hand, transient increases may be seen with inflam-
matory flares in chronic viral hepatitis. Published data at
the current moment suggest using values of >400 ng/ml
for diagnostic confirmation of HCC [67].
3. The diagnostic dilemma at the highly WD-HCC end is
that the hepatocytic histogenesis is obvious but proof of
malignancy may be lacking [24,32,33]. The cell cords tend
not to be >2 cells thick and the cellular pleomorphism
and subtle increase in the N/C ratios of the hepatocytes
may not be appreciated under light microscopy. In fact,
highly WD-HCC tend to be composed of small, uniform,
strikingly monotonous neoplastic hepatocytes with
slightly increased N/C ratios, imparting an impression of
nuclear crowding [34]. The recognition of polymorphism
with variation in cell and nuclear sizes and a normal N/C
ratio of 1/3 should alert one to the likelihood of benignity
of the hepatocytes [20].
4. Routine surveillance by more than one imaging tech-
nique in high-risk patients tends to detect nodule/s of var-
ious natures in the cirrhotic livers [10,71]. HCC tend to
occur in a cirrhotic background together with MRN and
low- and high-grade DN. Pure light microscopic interpre-
tation with immunohistochemical input may no longer
suffice in the diagnostic workup towards an accurate tis-
sue diagnosis.
5. Smaller and smaller lesions (<2 cm diameter) are being
increasingly detected by imaging and subjected to FNAB
for tissue diagnosis.CytoJournal 2005, 2:7 http://www.cytojournal.com/content/2/1/7
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6. Early HCC tend to be small and highly well-differenti-
ated, making differentiation from MRN and DN difficult.
Increasing numbers of equivocal nodular lesions are
being detected in cirrhotic livers by various imaging
modalities. The histopathologic interpretation of these
nodules is highly controversial, let alone cytologic assess-
ment. Eastern pathologists tend to call them early HCC
while the Western fraternity tends to go for a diagnosis of
high-grade DN [14,17].
7. Small HCC are prone to fatty change due to inadequate
neoangiogenesis; poor vascularity makes them difficult to
visualize and characterize by imaging methods [8,14].
Increasing degree of heterogeneity is exhibited as the
lesion enlarges [15].
8. Well-differentiated hepatocellular nodules of any
nature can occur in non-cirrhotic livers and have to be
distinguished from each other and from the surrounding
liver.
9. Fatty change can occur in WD-HCC, LCA, FNH and DN
without associated steatosis in the surrounding liver
parenchyma. An entity called focal fatty alteration/change
can also mimic these nodules [20,36].
10. Current histologic criteria for the diagnosis of highly
WD-HCC include loss of reticulin, thickening of trabecu-
lae (>2 cells thick), sinusoidal capillarization, unpaired
arterioles, cellular pleomorphism/heterogeneity, "clonal"
growth patterns, pseudoacini, mitotic activity [14,16] and
stromal invasion of portal tracts. Some of these criteria are
lacking in cytologic material.
11. In high-risk cases, some "non-malignant" nodules
with large cell change (low-grade DN) or small cell change
(high-grade DN) may be precursor lesions [11,18,72-74].
Morphometric studies suggest that small cell change may
be the more sinister lesion biologically. HCC occurs in 5–
40% of cirrhotic patients and foci of cancer are found in a
third of DN [75]. Some of these precursor lesions may be
indistinguishable from malignant hepatocellular nodules
by light microscopy alone.
12. Current concepts on how premalignant lesions
develop and how HCC may arise within them impact on
the accuracy of pathologic diagnosis of hepatocellular
nodules [7,9,10]. Inadequacies of FNAB evaluation of
hepatocellular nodules cannot be ignored given the focal-
ity of proliferative clones of atypical cells within the nod-
ules and the shortcomings of pure morphologic
interpretation.
Diagnostic utility of immunohistochemistry
There are two major applications for immunohistochem-
ical markers in the diagnostic workup of focal liver lesions
[20,76]. One is to decipher the exact histogenetic origin of
obvious tumor nodules – that is, the histologic typing and
the primary site [77]. It may not always be possible to dis-
tinguish between the poorly differentiated entities of
HCC, CC and metastatic carcinomas [25,78]. By the same
token, adenocarcinomas occurring in the liver may be
metastatic or primary in origin. Of interest lately is the
increasing documentation of AFP-producing extrahepatic
hepatoid/non-hepatoid carcinomas that have a
propensity for vascular invasion and liver metastases
[59,79]. The immunoprofile of these tumors, originating
mostly in the GIT and lungs, is almost identical to that of
HCC. Serum AFP levels tend to be very high. The other
application concerns the distinction of the various lesions
within the realm of well-differentiated hepatocellular
nodular lesions. [See "FNAB of well-differentiated hepatocel-
lular nodular lesions"]. For ascertainment of malignancy in
hepatocellular nodules, the antibody panel should com-
prise at least AFP, pCEA or CD10, and CD34 [80-82].
Additional markers, such as Hep Par 1 and cytokeratins,
should be included if the histogenesis of the tumor is to
be studied. Markers of cell proliferation, proliferating cell
nuclear antigen (PCNA) and Ki67; and p53 are not rou-
tinely used.
• AFP is fairly specific but not sensitive for HCC. Tissue
AFP immunoreactivity is expected in HCC (Figure 11) but
it may be patchy and minimal. Sensitivity is about 50%
(range, 20–75%) and is low at both ends of the histologic
spectrum of HCC [44,83-86]. A study of 56 patients with
small HCC (<2 cm diameter) showed AFP-positivity in
44.6% of the tumors [87]. A variable staining pattern may
be encountered with CHCC-CC. MRN in cirrhosis are not
associated with elevated serum or stainable tissue AFP
[88]; neither are DN or LCA. The specificity of AFP for
HCC is being challenged by reports of AFP-producing ext-
rahepatic hepatoid/non-hepatoid carcinomas [59]. There
is an increasing tendency to drop this immunomarker
from the panel for HCC workup.
• pCEA stains bile canaliculi and ductal epithelium but
not hepatocytes. A characteristic "chicken-wire fence"
canalicular staining pattern is seen in normal liver [89].
Biliary epithelial cells show diffuse cytoplasmic and brush
border staining. A normal canalicular pattern is expected
for benign hepatocellular nodular lesions. However, some
LCA and even, some FNH, may exhibit deficient
canaliculi. There are two patterns of staining in HCC –
canalicular and/or diffuse cytoplasmic staining. The
canalicular pattern is abnormal and deficient in HCC with
twisted and often dilated structures; it may not even be
appreciable in high-grade HCC [78]. Instead, diffuseCytoJournal 2005, 2:7 http://www.cytojournal.com/content/2/1/7
Page 13 of 16
(page number not for citation purposes)
cytoplasmic staining may be seen in less differentiated
HCC, making distinction from a poorly differentiated
adenocarcinoma difficult. In the context of a carcinoma, a
canalicular pattern is specific for HCC.
• CD10 is expressed in normal and neoplastic liver, exhib-
iting a similar canalicular staining pattern to pCEA
[90,91]. Although it does not differentiate between
benign and malignant hepatocellular nodular lesions,
CD10 is very useful in distinguishing HCC from non-
HCC malignancies. The sensitivity of CD10 (68.3%) is far
better than immuno-staining for AFP (23.8%) but less
sensitive than pCEA (95.2%) in the diagnosis of HCC
[92].
• Hep Par 1 (Hepatocyte antigen) is a sensitive marker
for hepatocytic differentiation and is part of the antibody
panel for distinguishing HCC from CC and metastases.
However, not all HCC stain uniformly (Figure 12) and
not all Hep Par 1-positive tumors are of hepatocellular
origin or arise in the liver [86,93-96]. Its variable and het-
erogeneous staining pattern, which can range from 100%
-positive cells in WD-HCC to <5% in some PD-HCC cases,
may lead to false negative results in small samples [97].
MRN, DN, FNH and LCA tend to exhibit 100% positivity.
Hence, this antibody has no discriminant value in the
evaluation of the biological status of well-differentiated
hepatocellular nodular lesions.
• Cytokeratins (CK 7, 8, 18, 19, 20; CAM 5.2; AE1/AE3).
Mature hepatocytes stain with CK 8 and 18 and CAM 5.2
but not with CK 7, 19 or 20 or AE1/AE3. CAM 5.2 is the
most reliable cytokeratin antibody for HCC. AE1/AE3
negativity is expected in hepatocellular lesions. Focal CK
7 and 19 positivity can be seen in high-grade HCC. HCC
is generally CK 20 negative [98].
• CD34 is an intercellular adhesion protein found in nor-
mal endothelium but absent in normal sinusoids. CD34
highlights regions of sinusoidal capillarization where
there is basement membrane material deposition. Diffuse
sinusoidal CD34 reactivity is seen in HCC, even small
WD-HCC [99]. However, significant reactivity is also seen
in LCA and some FNH. In cirrhotic and DN, staining is
absent or minimal, and confined to the periportal/peri-
septal regions [100].
Conclusion
Tissue confirmation is recommended in the diagnosis of
focal liver lesions as the risk of aggressive therapy is greater
than the risk of malignant seeding. FNAB has many
advantages that CNB lacks. The lack of tissue can be over-
come by using cutting aspiration needles that can provide
material for smear cytology and microhistology. Guided
FNAB is a highly operator-dependent procedure as is the
preparation and interpretation of the cytologic material.
Optimization of FNAB in the diagnosis of focal liver
lesions, increase in the yield of true positive diagnoses,
and rendering of fewer indeterminate reports require close
clinicopathologic correlation; combination of smear
cytology and microhistology, use of a discriminant panel
of special and immunostains; and team work by skilled
operators on all fronts.
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